Cycloset is first diabetes drug to clear US CV safety hurdle
This article was originally published in Scrip
Executive Summary
VeroScience/S2 Therapeutics' Cycloset (bromocriptine mesylate) has become the first new type 2 diabetes therapy to win US FDA licensing since the agency imposed stricter cardiovascular safety requirements for such drugs late last year.